Electroconvulsive Therapy plus Lithium is Associated with Less Cognitive Impairment and Drug-Induced Delirium in Bipolar Depression Compared to Unipolar Depression
Restricted accessResearch articleFirst published online March, 2023
Electroconvulsive Therapy plus Lithium is Associated with Less Cognitive Impairment and Drug-Induced Delirium in Bipolar Depression Compared to Unipolar Depression
Although major depressive disorder (MDD) and bipolar depression can present with similar symptoms, biological differences exist. One difference is the possible variance in adverse effects associated with treatment. This study examined the association of cognitive impairment and delirium in patients treated with electroconvulsive therapy (ECT) plus lithium for MDD or bipolar depression.
Methods
The Nationwide Inpatient Sample included 210 adults receiving ECT plus lithium. Descriptive statistics and a Chi-square test were used to evaluate the differences between mild cognitive impairment and drug-induced delirium for those with MDD or bipolar depression. We calculated the odds ratio (OR) for drug-induced delirium in inpatients with MDD (compared to inpatients with bipolar depression) using a binomial logistic regression model.
Results
Mild cognitive impairment was observed in 9.1% of patients with MDD (n = 110), compared to 0 in bipolar depression (n = 100) (P = .002). Drug-induced delirium was more prevalent in MDD (OR 1.19; 95% CI, 1.11 to 1.30).
Conclusions
ECT plus lithium is associated with less cognitive impairment and drug-induced delirium in bipolar depression compared to MDD. This study may also support biological differences between the 2 types of depression.
Get full access to this article
View all access options for this article.
References
1.
HashimotoK.Metabolomics of major depressive disorder and bipolar disorder: overview and future perspective. Adv Clin Chem. 2018;84:81–99.
2.
VöhringerPA, PerlisRH.Discriminating between bipolar disorder and major depressive disorder. Psychiatr ClinNorth Am. 2016;39(l):1–10.
3.
MacDonaldK, KrishnanA, CervenkaE, et al. Biomarkers for major depressive and bipolar disorders using metabolomics: a systematic review. Am J Med Genet B Neuro psychiatr Genet. 2019; 180(2):122–137.
4.
WoodruffDB, El-MallakhRS, ThiruvengadamAP.Validation of a diagnostic screening blood test for bipolar disorder. Ann Clin Psychiatry. 2012;24(2):135–139.
5.
GoldsmithDR, RapaportMH, MillerBJ.A metaanalysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016; 21(12):1696–1709.
6.
AquadroE, YoussefNA.Combine these screening tools to detect bipolar depression. J Fam Pract. 2018;67(8):500–503.
7.
WhittonAE, TreadwayMT, PizzagalliDA.Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry. 2015; 28(1):7–12.
8.
KroghJ, BenrosME, JorgensenMB, et al. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun. 2014;35:70–76.
9.
StrawbridgeR, CarterR, SaldariniF, et al. Inflammatory biomarkers and cognitive functioning in individuals with euthymic bipolar disorder: exploratory study. BJPsych Open. 2021;7(4):el26.
10.
SchoeyenHK, KesslerU, AndreassenOA, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172(1):41–51.
11.
MilsteinV, SmallJG.Problems with lithium combined with ECTAm J Psychiatry. 1988;145(9):1178.
12.
SmallJG, KellamsJJ, MilsteinV, et al. Complications with electroconvulsive treatment combined with lithium. Biol Psychiatry. 1980;15(1):103–112.
13.
DolencTJ, RasmussenKG.The safety of electroconvulsive therapy and lithium in combination: a case series and review of the literature. J ECT2005; 21(3):165–170.
14.
SadanandaSK, NarayanaswamyJC, SrinivasarajuR, et al. Delirium during the course of electroconvulsive therapy in a patient on lithium carbonate treatment. Gen Hosp Psychiatry. 2013;35(6):678.el-e2.
15.
WeinerRD, WhangerAD, ErwinCW, et al. Prolonged confusional state and EEG seizure activity following concurrent ECT and lithium use. Am J Psychiatry. 1980;137(11):1452–1453.
16.
PatelRS, BachuA, YoussefNA.Combination of lithium and electroconvulsive therapy (ECT) is associated with higher odds of delirium and cognitive problems in a large national sample across the United States. Brain Stimul. 2020;13(l):15–19.
17.
MorenoC, HasinDS, ArangoC, et al. Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disord. 2012;14(3):271–282.
18.
PatelRS, SreeramV, ThakurT, et al. A national study for regional variation of inpatient ECT utilization from 4,411 hospitals across the United States. Ann Clin Psychiatry. 2019;31(3):200–208.
GaoK, KempDE, GanocySJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203–209.
21.
GaoK, PappadopulosE, KarayalON, et al. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol. 2013;33(3):425–431.
22.
GaoK, GanocySJ, GajwaniP, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69(2):302–309.
23.
WangZ, KempDE, ChanPK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14(1): 131–142.
24.
Le-NiculescuH, RoseberryK, GillSS, et al. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomies, and repurposed drugs. Mol Psychiatry. 2021; 26(7):2776–2804.
25.
HongCJ, ChenTJ, YuYW, et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006;6(l):27–33.
26.
YuYW, TsaiSJ, LiouYJ, et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol. 2006; 16(7):498–503.
27.
SerrettiA, ArtioliP, LorenziC, et al. The C(-1019) G polymorphism of the 5-HT1A gene promoter and antidepressant responseinmood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004;7(4): 453–460.
